Skip to main content

Pharma/Regulatory

psoriatic.PIP_.JPG

Biologic Persistence in Psoriatic Arthritis and Psoriasis

May 19, 2022

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Read Article
Inflammation,reflex,neural

Inflammatory Arthritis Spread by ATP and Neural Crosstalk

May 19, 2022

A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk. Such findings may be important in disorders like rheumatoid arthritis (RA)

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
morbidity,covid,heart,lung,brain

Multimorbidity Burden in Rheumatoid Arthritis

May 17, 2022

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.



This population-based study examined prevalent RA as of January 2015 and sought to

Read Article
lumbar,spine,lbp,pain

Acute Inflammatory Responses Needed to Resolve Chronic Pain

May 16, 2022

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Read Article
FDA.Safety.jpg

Bimekizumab Development Delayed by FDA

May 16, 2022

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Read Article
RheumNow Podcast square

Methotrexate Monitoring (5.13.2022)

May 13, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.




  1. Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Read Article
bone.infection.gram_.rod_.jpg

Wiki Guidelines Approach to Pyogenic Osteomyelitis

May 12, 2022

A crowd sourced, WikiGuidelines approach to clinical treatment guideline development for pyogenic osteomyelitis yielded 7 important clinical questions, 2 clear treatment recommendations and 5 topic reviews to inform future treatment or investigations.



Some clinical scenarios may be

Read Article
psoriasis,arm,hand,rash,elbow

Bimekizumab's Favorable Safety Profile in Psoriasis

May 11, 2022

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

Read Article
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

May 11, 2022

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A



  • Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD

  • Drug Targeting in PsA Bruce Kirkham
Read Article
RA.Ow02.jpg

ASCORE: Seropositivity Favors Abatacept Drug Survival

May 10, 2022

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 



The study

Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
SpA,AS,fusion

Diagnostic Delays in Spondyloarthritis Still Prolonged

May 09, 2022

Previously quoted average  delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years. 



The diagnostic delay in axSpA has been attributed to a slower

Read Article
RheumNow Podcast square

What is JAKne? (5.6.2022)

May 06, 2022

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.




  1. Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Read Article
medical.marijuana

Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain

Creaky Joints
May 06, 2022

A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and

Read Article
acne

Acne with JAK Inhibitors

May 05, 2022

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

Read Article
myositis.jpg

BSR Guideline on Idiopathic Inflammatory Myopathy

May 05, 2022

The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.

Read Article
DMARDs,biologics,RA

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

May 04, 2022

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Read Article
RA, hands, MCP, deformity

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

MedPage Today
May 03, 2022

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.



Over that 17-year period, rates of Medicare

Read Article
FDA%20approved.jpg (keep)

Upadacitinib FDA Approved for Ankylosing Spondylitis

May 02, 2022

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.

Read Article
SI,sacroiliitis,erosion

Prolonged TNF Inhibitor Use Delays Sacroiliac Progression

Apr 28, 2022

While tumour necrosis factor inhibitors (TNFi) have been shown to alter/retard X-ray outcomes in peripheral inflammatory arthritis, the inhibitor effects of TNFi on axial skeletal progression in spondylitis has been difficult to prove, owing to difficulties in study design, identifying best

Read Article
TNRPSA,0426

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Apr 27, 2022

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Read Article
COVID,vaccinate,injection,green

Evusheld as Protective Therapy in High Risk COVID-19 Patients

Apr 21, 2022

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 



Both MAbs are neutralizing antibodies against SARS

Read Article
TNR,controversies,psa

TNR - Controversies in PsA

Apr 20, 2022

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.



The PsA Expert panelists included:



  • Dr. Dafna Gladman, Toronton

  • Dr. Joseph Merola, Boston

  • Dr. Peter
Read Article
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

Apr 15, 2022

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
×